CoChat
Sign Up
Cited by 37Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Alzheimer’s disease: diagnostics, prognostics and the road to prevention

Open access
Grossman, Iris, Lutz, Michael W., Crenshaw, Donna G., Saunders, Ann M., Burns, Daniel K., Roses, Allen D.·2010·EPMA Journal
DOI 10.1007/s13167-010-0024-3PMC PMC2987528
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) presents one of the leading healthcare challenges of the 21st century, with a projected worldwide prevalence of >107 million cases by 2025. While biomarkers have been identified, which may correlate with disease progression or subtype for the purpose of disease monitoring or differential diagnosis, a biomarker for reliable prediction of late onset disease risk has not been available until now. This deficiency in reliable predictive biomarkers, coupled with the devastating nature of the disease, places AD at a high priority for focus by predictive, preventive and personalized medicine. Recent data, discovered using phylogenetic analysis, suggest that a variable length poly-T sequence polymorphism in the TOMM40 gene, adjacent to the APOE gene, is predictive of risk of AD age-of-onset when coupled with a subject's current age. This finding offers hope for reliable assignment of disease risk within a 5-7 year window, and is expected to guide enrichment of clinical trials in order to speed development of preventative medicines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13167-010-0024-3

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 85

  1. [1]Matchar DB Thakur ME Grossman I Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs) Evid Rep Technol Assess (Full Rep) 2007 146 1 77 PMC4781099 17764209
  2. [3]Hughes B The comparative effectiveness challenge Nat Rev Drug Discov 2009 8 4 261 3 10.1038/nrd2866 19337261 · DOI
  3. [4]Ginsburg G SWillard HF Genomic and personalized medicine: foundations and applications Transl Res 2009 154 6 277 87 10.1016/j.trsl.2009.09.005 19931193 · DOI · Paper page
  4. [6]Hebert LE Scherr PA Bienias JL Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 2003 60 8 1119 22 10.1001/archneur.60.8.1119 12925369 · DOI · Paper page
  5. [8]Brookmeyer R Johnson E Ziegler-Graham K Forecasting the global burden of Alzheimer’s disease Alzheimers Dement 2007 3 3 186 91 10.1016/j.jalz.2007.04.381 19595937 · DOI · Paper page
  6. [9]Organization W H. The global burden of disease (2004 update). In. Geneva, Switzerland: WHO Press; 2004.
  7. [10]Blennow K de Leon M JZetterberg H Alzheimer’s disease Lancet 2006 368 9533 387 403 10.1016/S0140-6736(06)69113-7 16876668 · DOI · Paper page
  8. [11]West RL An application of prefrontal cortex function theory to cognitive aging Psychol Bull 1996 120 2 272 92 10.1037/0033-2909.120.2.272 8831298 · DOI
  9. [12]Visser PJ Verhey FR Mild cognitive impairment as predictor for Alzheimer’s disease in clinical practice: effect of age and diagnostic criteria Psychol Med 2008 38 1 113 22 10.1017/S0033291707000554 17451628 · DOI
  10. [14]Gatz M Reynolds CA Fratiglioni L Role of genes and environments for explaining Alzheimer disease Arch Gen Psychiatry 2006 63 2 168 74 10.1001/archpsyc.63.2.168 16461860 · DOI · Paper page
  11. [15]Goate A Chartier-Harlin MC Mullan M Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease Nature 1991 349 6311 704 6 10.1038/349704a0 1671712 · DOI · Paper page
  12. [16]Sherrington R Rogaev EI Liang Y Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease Nature 1995 375 6534 754 60 10.1038/375754a0 7596406 · DOI · Paper page
  13. [17]Levy-Lahad E Wasco W Poorkaj P Candidate gene for the chromosome 1 familial Alzheimer’s disease locus Science 1995 269 5226 973 7 10.1126/science.7638622 7638622 · DOI · Paper page
  14. [18]Rogaev EI Sherrington R Rogaeva EA Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene Nature 1995 376 6543 775 8 10.1038/376775a0 7651536 · DOI · Paper page
  15. [19]Campion D Dumanchin C Hannequin D Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum Am J Hum Genet 1999 65 3 664 70 10.1086/302553 10441572 PMC1377972 · DOI · Paper page
  16. [20]Pericak-Vance MA Grubber J Bailey LR Identification of novel genes in late-onset Alzheimer’s disease Exp Gerontol 2000 35 9–10 1343 52 10.1016/S0531-5565(00)00196-0 11113612 · DOI
  17. [21]Corder EH Saunders AM Strittmatter WJ Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families Science 1993 261 5123 921 3 10.1126/science.8346443 8346443 · DOI · Paper page
  18. [22]Rocchi A Pellegrini S Siciliano G Causative and susceptibility genes for Alzheimer’s disease: a review Brain Res Bull 2003 61 1 1 24 10.1016/S0361-9230(03)00067-4 12788204 · DOI
  19. [24]Mahley RW Apolipoprotein E: cholesterol transport protein with expanding role in cell biology Science 1988 240 4852 622 30 10.1126/science.3283935 3283935 · DOI · Paper page
  20. [25]Strittmatter WJ Saunders AM Schmechel D Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc Natl Acad Sci U S A 1993 90 5 1977 81 10.1073/pnas.90.5.1977 8446617 PMC46003 · DOI · Paper page
  21. [27]Farrer LA Cupples LA Haines JL Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium JAMA 1997 278 16 1349 56 10.1001/jama.278.16.1349 9343467 · DOI · Paper page
  22. [28]Roses AD Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease J Neuropathol Exp Neurol 1994 53 5 429 37 10.1097/00005072-199409000-00002 8083686 · DOI
  23. [29]Abraham R Moskvina V Sims R A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling BMC Med Genomics 2008 1 44 10.1186/1755-8794-1-44 18823527 PMC2570675 · DOI · Paper page
  24. [30]Li H Wetten S Li L Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease Arch Neurol. 2008 65 1 45 53 10.1001/archneurol.2007.3 17998437 · DOI · Paper page
  25. [31]Yu C-E Seltman H Peskind ER Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer’s disease: patterns of linkage disequilibrium and disease/marker association Genomics 2007 89 6 655 65 10.1016/j.ygeno.2007.02.002 17434289 PMC1978251 · DOI
  26. [32]Waring SC Rosenberg RN Genome-wide association studies in Alzheimer Disease Arch Neurol 2008 65 3 329 34 10.1001/archneur.65.3.329 18332245 · DOI
  27. [33]Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84(1):35–43. PMC2668056 19118814
  28. [34]Waring SC Rosenberg RN Genome-wide association studies in Alzheimer disease Arch Neurol 2008 65 3 329 34 10.1001/archneur.65.3.329 18332245 · DOI
  29. [35]Yu CE Seltman H Peskind ER Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer’s disease: patterns of linkage disequilibrium and disease/marker association Genomics 2007 89 6 655 65 10.1016/j.ygeno.2007.02.002 17434289 PMC1978251 · DOI
  30. [36]Bu G Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy Nat Rev Neurosci 2009 10 5 333 44 10.1038/nrn2620 19339974 PMC2908393 · DOI · Paper page
  31. [37]Cedazo-Minguez A Apolipoprotein E and Alzheimer’s disease: molecular mechanisms and therapeutic opportunities J Cell Mol Med 2007 11 6 1227 38 10.1111/j.1582-4934.2007.00130.x 18205697 PMC4401287 · DOI
  32. [38]Bazrgar M Karimi M Fathzadeh M Apolipoprotein E polymorphism in Southern Iran: E4 allele in the lowest reported amounts Mol Biol Rep 2008 35 4 495 9 10.1007/s11033-007-9113-3 17594534 · DOI
  33. [40]Mayeux R Saunders AM Shea S Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease N Engl J Med 1998 338 8 506 11 10.1056/NEJM199802193380804 9468467 · DOI · Paper page
  34. [41]Cichon S Craddock N Daly M Genomewide association studies: history, rationale, and prospects for psychiatric disorders Am J Psychiatry 2009 166 5 540 56 10.1176/appi.ajp.2008.08091354 19339359 PMC3894622 · DOI · Paper page
  35. [42]Bertram L McQueen MB Mullin K Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database Nat Genet 2007 39 1 17 23 10.1038/ng1934 17192785 · DOI · Paper page
  36. [43]Lyssenko VGroop L Genome-wide association study for type 2 diabetes: clinical applications Curr Opin Lipidol 2009 20 2 87 91 10.1097/MOL.0b013e32832923af 19276887 · DOI
  37. [44]McCarthy MI Zeggini E Genome-wide association studies in type 2 diabetes Curr Diab Rep 2009 9 2 164 71 10.1007/s11892-009-0027-4 19323962 PMC2694564 · DOI
  38. [45]Dickson SP Wang K Krantz I Rare variants create synthetic genome-wide associations PLoS Biol 2010 8 1 e1000294 10.1371/journal.pbio.1000294 20126254 PMC2811148 · DOI · Paper page
  39. [46]Goldstein DB Common genetic variation and human traits N Engl J Med 2009 360 17 1696 8 10.1056/NEJMp0806284 19369660 · DOI
  40. [47]Ioannidis JP Thomas GDaly MJ Validating, augmenting and refining genome-wide association signals Nat Rev Genet 2009 10 5 318 29 10.1038/nrg2544 19373277 PMC7877552 · DOI
  41. [48]Coon KD Myers AJ Craig DW A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease J Clin Psychiatry 2007 68 4 613 18 10.4088/JCP.v68n0419 17474819 · DOI · Paper page
  42. [51]Lambert JC Heath S Even G Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease Nat Genet 2009 41 10 1094 9 10.1038/ng.439 19734903 · DOI · Paper page
  43. [52]Heinzen EL, Need AC, Hayden KM et al. Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J Alzheimers Dis. 2009. PMID: 19749422 PMC2883723 20061627
  44. [53]Carrasquillo MM Zou F Pankratz VS Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease Nat Genet 2009 41 2 192 8 10.1038/ng.305 19136949 PMC2873177 · DOI · Paper page
  45. [54]Grupe A Abraham R Li Y Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants Hum Mol Genet 2007 16 8 865 73 10.1093/hmg/ddm031 17317784 · DOI · Paper page
  46. [55]Reiman EM Webster JA Myers AJ GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers Neuron 2007 54 5 713 20 10.1016/j.neuron.2007.05.022 17553421 PMC2587162 · DOI · Paper page
  47. [56]Bertram L Lange C Mullin K Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE Am J Hum Genet 2008 83 5 623 32 10.1016/j.ajhg.2008.10.008 18976728 PMC2668052 · DOI · Paper page
  48. [57]Blass JP Gibson GE Cerebrometabolic aspects of delirium in relationship to dementia Dement Geriatr Cogn Disord 1999 10 5 335 8 10.1159/000017165 10473934 · DOI
  49. [58]Davis JN Hunnicutt EJ Jr CJC A mitochondrial bottleneck hypothesis of Alzheimer’s disease Mol Med Today 1995 1 5 240 7 10.1016/S1357-4310(95)91532-X 17607886 · DOI
  50. [59]Kessler J Herholz K Grond M Impaired metabolic activation in Alzheimer’s disease: a PET study during continuous visual recognition Neuropsychologia 1991 29 3 229 43 10.1016/0028-3932(91)90084-L 2057055 · DOI
  51. [60]Blass JP The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome Ann N Y Acad Sci 2000 924 170 83 11193795
  52. [61]Castellani R Hirai K Aliev G Role of mitochondrial dysfunction in Alzheimer’s disease J Neurosci Res 2002 70 3 357 60 10.1002/jnr.10389 12391597 · DOI
  53. [62]Manczak M Anekonda TS Henson E Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression Hum Mol Genet 2006 15 9 1437 49 10.1093/hmg/ddl066 16551656 · DOI · Paper page
  54. [63]Reddy PH Beal MF Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease Trends Mol Med 2008 14 2 45 53 10.1016/j.molmed.2007.12.002 18218341 PMC3107703 · DOI · Paper page
  55. [64]Rui Y Tiwari P Xie Z Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons J Neurosci 2006 26 41 10480 7 10.1523/JNEUROSCI.3231-06.2006 17035532 PMC6674697 · DOI
  56. [66]Brodbeck J Balestra ME Saunders AM Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons Proc Natl Acad Sci U S A 2008 105 4 1343 6 10.1073/pnas.0709906104 18212130 PMC2234140 · DOI · Paper page
  57. [69]Hansson Petersen CA Alikhani N Behbahani H The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae Proc Natl Acad Sci U S A 2008 105 35 13145 50 10.1073/pnas.0806192105 18757748 PMC2527349 · DOI · Paper page
  58. [70]Roses AD, Lutz MW, Amrine-Madsen H et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacogenom J. 2009. PMID: 20029386. PMC2946560 20029386
  59. [71]Bekris LM Millard SP Galloway NM Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels J Alzheimers Dis 2008 13 3 255 66 18430993 PMC3192652
  60. [72]Tachmazidou I JDe VC Iorio M Genetic association mapping via evolution-based clustering of haplotypes PLoS Genet 2007 3 7 e111 10.1371/journal.pgen.0030111 17616979 PMC1913101 · DOI
  61. [74]Wray GA The evolutionary significance of cis-regulatory mutations Nat Rev Genet 2007 8 3 206 16 10.1038/nrg2063 17304246 · DOI · Paper page
  62. [75]Biswas TK Getz GS Position-specific inhibition of yeast mitochondrial transcription by a poly(T) sequence J Mol Biol 1998 275 4 547 60 10.1006/jmbi.1997.1483 9466930 · DOI
  63. [76]Beyer K Humbert J Ferrer A A variable poly-T sequence modulates alpha-synuclein isoform expression and is associated with aging J Neurosci Res 2007 85 7 1538 46 10.1002/jnr.21270 17387688 · DOI
  64. [77]Hegde S Lenox LE Lariviere A An intronic sequence mutated in flexed-tail mice regulates splicing of Smad5 Mamm Genome 2007 18 12 852 60 10.1007/s00335-007-9074-9 18060457 · DOI
  65. [78]Chu CS Trapnell BC Curristin S Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA Nat Genet 1993 3 2 151 6 10.1038/ng0293-151 7684646 · DOI
  66. [79]Lutz MW, Crenshaw DG, Saunders AM et al. Perspectives: genetic variation at a single locus and age of onset for Alzheimer’s disease. Alzheimer’s and Dementia. 2010. PMID: PMC2874876 20298972
  67. [80]Motter R Vigo-Pelfrey C Kholodenko D Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease Ann Neurol 1995 38 4 643 8 10.1002/ana.410380413 7574461 · DOI · Paper page
  68. [81]Jagust WJ Landau SM Shaw LM Relationships between biomarkers in aging and dementia Neurology 2009 73 15 1193 9 10.1212/WNL.0b013e3181bc010c 19822868 PMC2764726 · DOI · Paper page
  69. [82]Fernhoff PM Newborn screening for genetic disorders Pediatr Clin North Am 2009 56 3 505 13 10.1016/j.pcl.2009.03.002 19501689 · DOI
  70. [83]Rosner G Rosner SOrr-Urtreger A Genetic testing in Israel: an overview Annu Rev Genomics Hum Genet 2009 10 175 92 10.1146/annurev.genom.030308.111406 19453249 · DOI
  71. [84]Hahn NM Kelley MR Klaunig JE Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications Future Oncol 2007 3 6 665 82 10.2217/14796694.3.6.665 18041919 · DOI
  72. [85]Palomaki GE Steinort K Knight GJ Comparing three screening strategies for combining first- and second-trimester Down syndrome markers Obstet Gynecol 2006 107 2 Pt 1 367 75 16449126
  73. [86]Lalonde RG, Thomas R, Rachlis A et al. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens. 2009. PMID: 19843279. 19843279
  74. [87]Grossman I Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 2007 8 10 1449 59 10.2217/14622416.8.10.1449 17979518 · DOI
  75. [88]Roses AD The medical and economic roles of pipeline pharmacogenetics: Alzheimer’s disease as a model of efficacy and HLA-B(*)5701 as a model of safety Neuropsychopharmacology 2009 34 1 6 17 10.1038/npp.2008.153 18923406 · DOI
  76. [89]Berson A Knobloch M Hanan M Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology Brain 2008 131 Pt 1 109 19 18056160
  77. [90]Podoly E Shalev DE Shenhar-Tsarfaty S The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology J Biol Chem 2009 284 25 17170 9 10.1074/jbc.M109.004952 19383604 PMC2719355 · DOI
  78. [91]Sjogren M Hesse C Basun H Tacrine and rate of progression in Alzheimer’s disease–relation to ApoE allele genotype J Neural Transm 2001 108 4 451 8 10.1007/s007020170066 11475012 · DOI
  79. [92]Choi SH Kim SY Na HR Effect of ApoE genotype on response to donepezil in patients with Alzheimer’s disease Dement Geriatr Cogn Disord 2008 25 5 445 50 10.1159/000124752 18401173 · DOI
  80. [93]Cacabelos R Llovo R Fraile C Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics Curr Alzheimer Res 2007 4 4 479 500 10.2174/156720507781788846 17908053 · DOI
  81. [94]Varsaldi F Miglio G Scordo MG Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients Eur J Clin Pharmacol 2006 62 9 721 6 10.1007/s00228-006-0168-1 16845507 · DOI
  82. [96]Kaufer D Gandy S APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics Neurology 2009 73 24 2052 3 10.1212/WNL.0b013e3181c6784a 19923549 · DOI · Paper page
  83. [97]Risner ME Saunders AM Altman JF Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease Pharmacogenomics J 2006 6 4 246 54 16446752
  84. [98]Costantini LC Barr LJ Vogel JL Hypometabolism as a therapeutic target in Alzheimer’s disease BMC Neurosci 2008 9 Suppl 2 S16 10.1186/1471-2202-9-S2-S16 19090989 PMC2604900 · DOI · Paper page
  85. [99]Akkari PA Swanson TW Crenshaw DG Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development Curr Pharm Des 2009 15 32 3754 63 10.2174/138161209789649538 19925426 · DOI

Cited by

Sorted by citations

Authors
Grossman, I., Lutz, M. W., Crenshaw, D. G., Saunders, A. M., Burns, D. K., & Roses, A. D.
Affiliations
Duke University (US)
Corresponding author
Roses, Allen D.
ORCID
Venue
EPMA Journal
Publisher
Springer Science and Business Media LLC
Published
2010-06
Volume
1
Issue
2
Pages
293-303
ISSN
  • 1878-5077 (ISSN-L)
  • 1878-5085
DOI
10.1007/s13167-010-0024-3
PMC
PMC2987528
OpenAlex
W1977828017
Cited by
37
References
10
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 5 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 8
FWCI
3.50
Type
journal article
Language
en
Open access
Licence
Locations
  • The EPMA Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG028377, AG028377)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Alzheimer's disease, predictive biomarkers, TOMM40, apolipoprotein E, disease risk prediction, preventive medicine, personalized medicine, clinical trial enrichment, phylogenetic analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review